X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8771) 8771
Book Review (1200) 1200
Publication (909) 909
Newsletter (681) 681
Conference Proceeding (248) 248
Book Chapter (40) 40
Newspaper Article (28) 28
Dissertation (19) 19
Magazine Article (11) 11
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
erlotinib (7432) 7432
index medicus (6036) 6036
humans (5878) 5878
oncology (4737) 4737
gefitinib (3382) 3382
female (3021) 3021
lung neoplasms - drug therapy (2965) 2965
male (2738) 2738
erlotinib hydrochloride (2706) 2706
chemotherapy (2617) 2617
carcinoma, non-small-cell lung - drug therapy (2544) 2544
cancer (2457) 2457
middle aged (2365) 2365
aged (2216) 2216
mutation (1965) 1965
receptor, epidermal growth factor - antagonists & inhibitors (1921) 1921
lung cancer, non-small cell (1900) 1900
quinazolines - therapeutic use (1748) 1748
lung cancer (1717) 1717
receptor, epidermal growth factor - genetics (1654) 1654
lung neoplasms - genetics (1624) 1624
lung neoplasms - pathology (1602) 1602
adult (1599) 1599
protein kinase inhibitors - therapeutic use (1555) 1555
antineoplastic agents - therapeutic use (1552) 1552
care and treatment (1520) 1520
egfr (1493) 1493
epidermal growth factor (1417) 1417
cell lung-cancer (1325) 1325
carcinoma, non-small-cell lung - genetics (1306) 1306
growth-factor receptor (1283) 1283
research (1266) 1266
treatment outcome (1255) 1255
carcinoma, non-small-cell lung - pathology (1227) 1227
respiratory system (1211) 1211
non-small cell lung cancer (1115) 1115
aged, 80 and over (1093) 1093
open-label (1089) 1089
antineoplastic combined chemotherapy protocols - therapeutic use (1037) 1037
adenocarcinoma (1020) 1020
quinazolines - administration & dosage (967) 967
therapy (966) 966
cell line, tumor (963) 963
animals (940) 940
analysis (906) 906
quinazolines - pharmacology (885) 885
tyrosine kinase inhibitors (873) 873
epidermal growth factor receptor (870) 870
tyrosine kinase inhibitor (857) 857
survival (835) 835
mutations (815) 815
tyrosine (811) 811
prognosis (805) 805
receptor, epidermal growth factor - metabolism (802) 802
acquired-resistance (801) 801
1st-line treatment (792) 792
respiratory tract diseases (789) 789
protein kinase inhibitors - pharmacology (780) 780
disease-free survival (767) 767
quinazolines - adverse effects (762) 762
nsclc (758) 758
pharmacology & pharmacy (752) 752
genetic aspects (748) 748
tumors (746) 746
drug therapy (739) 739
neoplasm staging (710) 710
antineoplastic agents - pharmacology (706) 706
adenocarcinoma - drug therapy (685) 685
bevacizumab (679) 679
trial (676) 676
hematology, oncology and palliative medicine (671) 671
lung neoplasms - mortality (665) 665
metastasis (652) 652
cetuximab (646) 646
phase-iii trial (638) 638
multicenter (630) 630
mice (619) 619
expression (601) 601
health aspects (599) 599
carcinoma, non-small-cell lung - mortality (585) 585
resistance (580) 580
clinical trials (569) 569
gemcitabine (560) 560
retrospective studies (546) 546
cancer therapies (528) 528
medicine & public health (524) 524
kinases (493) 493
antineoplastic agents - adverse effects (492) 492
oncology, experimental (492) 492
protein kinase inhibitors - adverse effects (491) 491
article (489) 489
egfr mutations (486) 486
lung neoplasms - metabolism (486) 486
combination (482) 482
non-small-cell lung cancer (472) 472
lung cancer, small cell (470) 470
patients (458) 458
egfr mutation (454) 454
adenocarcinoma - genetics (450) 450
pancreatic cancer (449) 449
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9237) 9237
French (163) 163
German (85) 85
Chinese (76) 76
Japanese (48) 48
Korean (41) 41
Spanish (39) 39
Portuguese (14) 14
Czech (11) 11
Hungarian (10) 10
Polish (8) 8
Turkish (8) 8
Dutch (5) 5
Italian (5) 5
Russian (3) 3
Danish (2) 2
Norwegian (2) 2
Croatian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Diagnosis & Therapy, ISSN 1177-1062, 01/2013, Volume 17, Issue 1, p. 57
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 55, pp. 131 - 139
Abstract Aim The aim of this study was to investigate if biomarkers of individual drug metabolism, respectively, the erlotinib/O-desmethyl-erlotinib metabolic... 
Hematology, Oncology and Palliative Medicine | Erlotinib/O-desmethyl-erlotinib ratio | EGFR inhibitor-induced skin rash | Erlotinib metabolic ratio | Predictive biomarker | PLUS GEMCITABINE | MANAGEMENT | PANCREATIC-CANCER | PHASE-III | TOXICITY | CELL LUNG-CANCER | THERAPY | PHARMACOKINETICS | ONCOLOGY | RECEPTOR TYROSINE KINASE | ADVERSE EVENTS | Exanthema - diagnosis | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Protein Kinase Inhibitors - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Erlotinib Hydrochloride - pharmacokinetics | Adenocarcinoma - blood | Pancreatic Neoplasms - pathology | Adenocarcinoma - drug therapy | Disease Progression | Protein Kinase Inhibitors - blood | Erlotinib Hydrochloride - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - enzymology | Germany | Lung Neoplasms - pathology | Pancreatic Neoplasms - drug therapy | Drug Dosage Calculations | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Biotransformation | Adult | Female | Pancreatic Neoplasms - mortality | Carcinoma, Non-Small-Cell Lung - pathology | Severity of Illness Index | Pancreatic Neoplasms - blood | Dealkylation | Adenocarcinoma - enzymology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Pancreatic Neoplasms - enzymology | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - blood | Aged | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Epidermal growth factor | Erlotinib | Skin care products | Physiological aspects | Rash (Dermatology) | Skin | Biological markers | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2016, Volume 34, Issue 33, pp. 4054 - U187
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | CLATHRIN-MEDIATED ENDOCYTOSIS | CELLS | DRUG-DELIVERY | CHITOSAN | TUMOR | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | PACLITAXEL | NANOPARTICLES | ENHANCED PERMEABILITY | CANCER-TREATMENT | PHARMACOLOGY & PHARMACY | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 3/2019, Volume 53, Issue 3, pp. 321 - 322
Journal Article
by Wu, Yi-Long and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of Oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Biomaterials, ISSN 0142-9612, 11/2017, Volume 145, pp. 56 - 71
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2016, Volume 34, Issue 33, pp. 4055 - U190
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 5, pp. 606 - 619
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2016, Volume 22, Issue 7, pp. 1827 - 1827
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 10/2017, Volume 27, Issue 19, pp. 4552 - 4557
Molecular imaging using radiolabeled Tyrosine Kinase Inhibitors (TKI) is a promising strategy for detection and staging of EGFR-positive cancers. A novel... 
Erlotinib | Tyrosine Kinase Inhibitors | PET imaging | 68Ga | p-NCS-Bn-NOTA | EGFR | 68Ga-NOTA-Erlotinib | Ga-NOTA-Erlotinib | Index Medicus
Journal Article
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 07/2009, Volume 19, Issue 5, pp. 929 - 933
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 01/2017, Volume 246, pp. 120 - 132
In this study, we demonstrate for the first time the concurrent transdermal delivery of erlotinib and IL36α siRNA as a potential dual therapy for psoriasis.... 
Gene delivery | siRNA | Transdermal | Psoriasis | Skin delivery | Lipid nanocarriers | CARRIERS | CHEMISTRY, MULTIDISCIPLINARY | GROWTH-FACTOR RECEPTOR | NANOPARTICLES | INHIBITION | THERAPY | IN-VIVO | PHARMACOLOGY & PHARMACY | TRANSDERMAL DRUG-DELIVERY | LIPOSOMES | PERCUTANEOUS DELIVERY | TOPICAL DELIVERY | Interleukin-1 - genetics | Skin - metabolism | Humans | Male | Administration, Cutaneous | Drug Delivery Systems | Psoriasis - genetics | Psoriasis - pathology | HEK293 Cells | Skin - pathology | Psoriasis - therapy | Protein Kinase Inhibitors - pharmacokinetics | Gene Transfer Techniques | Psoriasis - drug therapy | Erlotinib Hydrochloride - pharmacokinetics | RNA, Small Interfering - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | RNAi Therapeutics - methods | Protein Kinase Inhibitors - administration & dosage | Animals | Protein Kinase Inhibitors - therapeutic use | RNA, Small Interfering - therapeutic use | Erlotinib Hydrochloride - therapeutic use | RNA, Small Interfering - administration & dosage | Skin - drug effects | Atomic force microscopy | Erlotinib | Fluorescein | Skin care products | Skin | Drug therapy | Transdermal medication | Dermatology | Drugstores | Dermatologic agents | Tacrolimus | Pharmacy | Formulae, receipts, prescriptions | Mice | Index Medicus
Journal Article